pravastatin

• cancer risk modification by participant age (meta-regression)

  increases, p = 0.006

  the age of study participants significantly modified the effect of pravastatin therapy on cancer risk (p = 0.006)

  PMID:17325332 · one of two readings recorded this

• cancer risk

  no effect, n = 42902

  fixed-effects (risk ratio [RR] 1.06, 95% CI 0.99 - 1.13)

  PMID:17325332 · one of two readings recorded this

• cancer risk

  no effect, n = 42902

  random-effects model (RR 1.06, 95% CI 0.97 - 1.14)

  PMID:17325332 · one of two readings recorded this

• all strokes, adjusted HR

  no effect

  All Strokes, HR (95%CI) | 0.96 (0.64–1.43) | 0.95 (0.61–1.48)

  PMID:28924103 · one of two readings recorded this

• all strokes, adjusted HR

  no effect

  All Strokes, HR (95%CI) | 0.96 (0.64–1.43) | 0.95 (0.61–1.48)

  PMID:28924103 · one of two readings recorded this

• all strokes, n (%) of patients

  All Strokes, n (%) | 47 (11.0) | 38 (10.4) | 49 (11.8) | 41 (11.1)

  PMID:28924103 · one of two readings recorded this

• all strokes, n (%) of patients

  All Strokes, n (%) | 47 (11.0) | 38 (10.4) | 49 (11.8) | 41 (11.1)

  PMID:28924103 · one of two readings recorded this

• atherothrombotic infarction, n (%) of patients

  Atherothrombotic infarction, n (%) | 5 (1.2) | 3 (0.8) | 18 (4.3) | 7 (1.9)

  PMID:28924103 · one of two readings recorded this

• atherothrombotic infarction, n (%) of patients

  Atherothrombotic infarction, n (%) | 5 (1.2) | 3 (0.8) | 18 (4.3) | 7 (1.9)

  PMID:28924103 · one of two readings recorded this

• atherothrombotic stroke, incidence and adjusted HR

  decreases, p = 0.011

  (Fig. 1B; 0.24 vs. 0.88%/year, p = 0.011, adjusted HR 0.30 [95% CI 0.11 to 0.80])

  PMID:28924103 · one of two readings recorded this

• atherothrombotic stroke, incidence and adjusted HR

  no effect, p = 0.29

  (Fig. 2B; 0.17 vs. 0.39%/year, p = 0.29, adjusted HR 0.49 [95% CI 0.13 to 1.90])

  PMID:28924103 · one of two readings recorded this

• atherothrombotic stroke incidence, early vs late cohort

  decreases, p = 0.049

  The incidence of atherothrombotic stroke was significantly higher in the early cohort compared with the late cohort among control patients (0.88 vs. 0.39%/year, p = 0.049)

  PMID:28924103 · one of two readings recorded this

• cardioembolic infarction, adjusted HR

  no effect

  Cardioembolic infarction, HR (95%CI) | 5.26 (0.61–45.06) | 1.00 (0.14–7.08)

  PMID:28924103 · one of two readings recorded this

• cardioembolic infarction, adjusted HR

  no effect

  Cardioembolic infarction, HR (95%CI) | 5.26 (0.61–45.06) | 1.00 (0.14–7.08)

  PMID:28924103 · one of two readings recorded this

• cardioembolic infarction, n (%) of patients

  Cardioembolic infarction, n (%) | 5 (1.2) | 2 (0.5) | 1 (0.2) | 2 (0.5)

  PMID:28924103 · one of two readings recorded this

• cardioembolic infarction, n (%) of patients

  Cardioembolic infarction, n (%) | 5 (1.2) | 2 (0.5) | 1 (0.2) | 2 (0.5)

  PMID:28924103 · one of two readings recorded this

• death, n (%) of patients

  Death, n (%) | 24 (5.6) | 19 (5.2) | 19 (4.6) | 16 (4.3)

  PMID:28924103 · one of two readings recorded this

• death, n (%) of patients

  Death, n (%) | 24 (5.6) | 19 (5.2) | 19 (4.6) | 16 (4.3)

  PMID:28924103 · one of two readings recorded this

• hospitalization, n (%) of patients

  Hospitalization, n (%) | 128 (30.0) | 107 (29.2) | 113 (27.1) | 119 (32.3)

  PMID:28924103 · one of two readings recorded this

• hospitalization, n (%) of patients

  Hospitalization, n (%) | 128 (30.0) | 107 (29.2) | 113 (27.1) | 119 (32.3)

  PMID:28924103 · one of two readings recorded this

• incidence of all strokes per 100 person-year

  Incidence, 100 person-year | 2.40 | 2.29 | 2.53 | 2.41

  PMID:28924103 · one of two readings recorded this

• incidence of all strokes per 100 person-year

  Incidence, 100 person-year | 2.40 | 2.29 | 2.53 | 2.41

  PMID:28924103 · one of two readings recorded this

• incidence of atherothrombotic stroke, and of stroke plus TIA, pravastatin 10 mg/day versus no statin, reported only separately for patients enrolled within 6 months and later than 6 months after the initial stroke (post-hoc analysis of J-STARS)

  decreases, p = 0.011

  Not recorded as a finding: every result is a subgroup, with no whole-population estimate

  By contrast, the incidence of atherothrombotic stroke was significantly lower in the pravastatin group compared with the control group among patients in the early cohort, (Fig. 1B; 0.24 vs. 0.88%/year, p = 0.011, adjusted HR 0.30 [95% CI 0.11 to 0.80]).

  PMID:28924103 · one of two readings recorded this

• incidence of cardioembolic infarction per 100 person-year

  Incidence, 100 person-year | 0.24 | 0.11 | 0.05 | 0.11

  PMID:28924103 · one of two readings recorded this

• incidence of cardioembolic infarction per 100 person-year

  Incidence, 100 person-year | 0.24 | 0.11 | 0.05 | 0.11

  PMID:28924103 · one of two readings recorded this

• incidence of death per 100 person-year

  Incidence, 100 person-year | 1.14 | 1.08 | 0.92 | 0.89

  PMID:28924103 · one of two readings recorded this

• incidence of death per 100 person-year

  Incidence, 100 person-year | 1.14 | 1.08 | 0.92 | 0.89

  PMID:28924103 · one of two readings recorded this

• incidence of hospitalization per 100 person-year

  Incidence, 100 person-year | 7.38 | 7.30 | 6.55 | 7.84

  PMID:28924103 · one of two readings recorded this

• incidence of hospitalization per 100 person-year

  Incidence, 100 person-year | 7.38 | 7.30 | 6.55 | 7.84

  PMID:28924103 · one of two readings recorded this

• incidence of intracranial hemorrhage per 100 person-year

  Incidence, 100 person-year | 0.29 | 0.34 | 0.39 | 0.22

  PMID:28924103 · one of two readings recorded this

• incidence of intracranial hemorrhage per 100 person-year

  Incidence, 100 person-year | 0.29 | 0.34 | 0.39 | 0.22

  PMID:28924103 · one of two readings recorded this

• incidence of lacunar infarction per 100 person-year

  Incidence, 100 person-year | 1.29 | 1.23 | 1.00 | 1.03

  PMID:28924103 · one of two readings recorded this

• incidence of lacunar infarction per 100 person-year

  Incidence, 100 person-year | 1.29 | 1.23 | 1.00 | 1.03

  PMID:28924103 · one of two readings recorded this

• incidence of myocardial infarction per 100 person-year

  Incidence, 100 person-year | 0.14 | 0.06 | 0.10 | 0.28

  PMID:28924103 · one of two readings recorded this

• incidence of myocardial infarction per 100 person-year

  Incidence, 100 person-year | 0.14 | 0.06 | 0.10 | 0.28

  PMID:28924103 · one of two readings recorded this

• incidence of stroke and TIA per 100 person-year

  Incidence, 100 person-year | 2.74 | 2.36 | 2.70 | 2.60

  PMID:28924103 · one of two readings recorded this

• incidence of stroke and TIA per 100 person-year

  Incidence, 100 person-year | 2.74 | 2.36 | 2.70 | 2.60

  PMID:28924103 · one of two readings recorded this

• incidence of TIA per 100 person-year

  Incidence, 100 person-year | 0.29 | 0.11 | 0.19 | 0.22

  PMID:28924103 · one of two readings recorded this

• incidence of TIA per 100 person-year

  Incidence, 100 person-year | 0.29 | 0.11 | 0.19 | 0.22

  PMID:28924103 · one of two readings recorded this

• incidence of vascular accidents per 100 person-year

  Incidence, 100 person-year | 3.37 | 3.01 | 3.58 | 3.95

  PMID:28924103 · one of two readings recorded this

• incidence of vascular accidents per 100 person-year

  Incidence, 100 person-year | 3.37 | 3.01 | 3.58 | 3.95

  PMID:28924103 · one of two readings recorded this

• interaction of pravastatin effect on atherothrombotic stroke by early vs late cohort

  no effect, p = 0.59

  this difference of pravastatin effect on atherothrombotic stroke was not significantly interacted by the early or late cohort (p = 0.59)

  PMID:28924103 · one of two readings recorded this

• intracranial hemorrhage, adjusted HR

  no effect

  Intracranial hemorrhage, HR (95%CI) | 0.73 (0.25–2.11) | 1.53 (0.43–5.44)

  PMID:28924103 · one of two readings recorded this

• intracranial hemorrhage, adjusted HR

  no effect

  Intracranial hemorrhage, HR (95%CI) | 0.73 (0.25–2.11) | 1.53 (0.43–5.44)

  PMID:28924103 · one of two readings recorded this

• intracranial hemorrhage, n (%) of patients

  Intracranial hemorrhage, n (%) | 6 (1.4) | 6 (1.6) | 8 (1.9) | 4 (1.1)

  PMID:28924103 · one of two readings recorded this

• intracranial hemorrhage, n (%) of patients

  Intracranial hemorrhage, n (%) | 6 (1.4) | 6 (1.6) | 8 (1.9) | 4 (1.1)

  PMID:28924103 · one of two readings recorded this

• lacunar infarction, adjusted HR

  no effect

  Lacunar infarction, HR (95%CI) | 1.28 (0.72–2.30) | 1.17 (0.62–2.20)

  PMID:28924103 · one of two readings recorded this

• lacunar infarction, adjusted HR

  no effect

  Lacunar infarction, HR (95%CI) | 1.28 (0.72–2.30) | 1.17 (0.62–2.20)

  PMID:28924103 · one of two readings recorded this

• lacunar infarction, n (%) of patients

  Lacunar infarction, n (%) | 26 (6.1) | 21 (5.7) | 20 (4.8) | 18 (4.9)

  PMID:28924103 · one of two readings recorded this

• lacunar infarction, n (%) of patients

  Lacunar infarction, n (%) | 26 (6.1) | 21 (5.7) | 20 (4.8) | 18 (4.9)

  PMID:28924103 · one of two readings recorded this

• myocardial infarction, n (%) of patients

  Myocardial infarction, n (%) | 3 (0.7) | 1 (0.3) | 2 (0.5) | 5 (1.4)

  PMID:28924103 · one of two readings recorded this

• myocardial infarction, n (%) of patients

  Myocardial infarction, n (%) | 3 (0.7) | 1 (0.3) | 2 (0.5) | 5 (1.4)

  PMID:28924103 · one of two readings recorded this

• stroke and TIA, incidence and adjusted HR

  no effect, p = 0.92

  (Fig. 1A; 2.74 vs. 2.70%/year, p = 0.92, adjusted HR 1.02 [95% CI 0.70 to 1.50])

  PMID:28924103 · one of two readings recorded this

• stroke and TIA, incidence and adjusted HR

  no effect, p = 0.64

  (Fig. 1A; 2.36 vs. 2.60%/year, p = 0.64, adjusted HR 0.90 [95% CI 0.59 to 1.39])

  PMID:28924103 · one of two readings recorded this

• stroke and TIA incidence, early vs late cohort

  no effect, p = 0.42

  The incidence of stroke and TIA was similar in the early cohort and in the late cohort (2.48 vs. 2.78%/year, p = 0.42)

  PMID:28924103 · one of two readings recorded this

• stroke and TIA, n (%) of patients

  Stroke and TIA, n (%) | 53 (12.4) | 39 (10.6) | 52 (12.5) | 44 (12.0)

  PMID:28924103 · one of two readings recorded this

• stroke and TIA, n (%) of patients

  Stroke and TIA, n (%) | 53 (12.4) | 39 (10.6) | 52 (12.5) | 44 (12.0)

  PMID:28924103 · one of two readings recorded this

• TIA, adjusted HR

  no effect

  TIA, HR (95%CI) | 1.41 (0.42–5.21) | 0.51 (0.09–2.79)

  PMID:28924103 · one of two readings recorded this

• TIA, adjusted HR

  no effect

  TIA, HR (95%CI) | 1.41 (0.42–5.21) | 0.51 (0.09–2.79)

  PMID:28924103 · one of two readings recorded this

• TIA, n (%) of patients

  TIA, n (%) | 6 (1.4) | 2 (0.5) | 4 (1.0) | 4 (1.1)

  PMID:28924103 · one of two readings recorded this

• TIA, n (%) of patients

  TIA, n (%) | 6 (1.4) | 2 (0.5) | 4 (1.0) | 4 (1.1)

  PMID:28924103 · one of two readings recorded this

• vascular accidents, n (%) of patients

  Vascular accidents, n (%) | 64 (15.0) | 49 (13.4) | 67 (16.1) | 65 (17.7)

  PMID:28924103 · one of two readings recorded this

• vascular accidents, n (%) of patients

  Vascular accidents, n (%) | 64 (15.0) | 49 (13.4) | 67 (16.1) | 65 (17.7)

  PMID:28924103 · one of two readings recorded this

• HDL cholesterol

  no effect

  High-density lipoprotein cholesterol was not significantly different between the 2 groups

  PMID:29191850 · one of two readings recorded this

• annual change in maximum IMT

  no effect, p = 0.62

  0.012±0.188, 0.010±0.270, 0.015±0.275, −0.005±0.265, and 0.014±0.252 mm in the pravastatin group and 0.006±0.148 mm (P=0.62), 0.018±0.184 mm (P=0.27), 0.020±0.189 mm (P=0.30), 0.034±0.236 mm (P=0.040), and 0.044±0.300 mm (P=0.40)

  PMID:29191850 · one of two readings recorded this

• annual change in maximum IMT

  no effect, p = 0.27

  0.012±0.188, 0.010±0.270, 0.015±0.275, −0.005±0.265, and 0.014±0.252 mm in the pravastatin group and 0.006±0.148 mm (P=0.62), 0.018±0.184 mm (P=0.27), 0.020±0.189 mm (P=0.30), 0.034±0.236 mm (P=0.040), and 0.044±0.300 mm (P=0.40)

  PMID:29191850 · one of two readings recorded this

• annual change in maximum IMT

  no effect, p = 0.3

  0.012±0.188, 0.010±0.270, 0.015±0.275, −0.005±0.265, and 0.014±0.252 mm in the pravastatin group and 0.006±0.148 mm (P=0.62), 0.018±0.184 mm (P=0.27), 0.020±0.189 mm (P=0.30), 0.034±0.236 mm (P=0.040), and 0.044±0.300 mm (P=0.40)

  PMID:29191850 · one of two readings recorded this

• annual change in maximum IMT

  decreases, p = 0.04

  0.012±0.188, 0.010±0.270, 0.015±0.275, −0.005±0.265, and 0.014±0.252 mm in the pravastatin group and 0.006±0.148 mm (P=0.62), 0.018±0.184 mm (P=0.27), 0.020±0.189 mm (P=0.30), 0.034±0.236 mm (P=0.040), and 0.044±0.300 mm (P=0.40)

  PMID:29191850 · one of two readings recorded this

• annual change in maximum IMT

  no effect, p = 0.4

  0.012±0.188, 0.010±0.270, 0.015±0.275, −0.005±0.265, and 0.014±0.252 mm in the pravastatin group and 0.006±0.148 mm (P=0.62), 0.018±0.184 mm (P=0.27), 0.020±0.189 mm (P=0.30), 0.034±0.236 mm (P=0.040), and 0.044±0.300 mm (P=0.40)

  PMID:29191850 · one of two readings recorded this

• annual change in maximum IMT

  no effect, p = 0.78

  0.017±0.190, 0.016±0.225, 0.017±0.263, 0.002±0.251, and 0.017±0.246 mm in the pravastatin group and 0.008±0.148 mm (P=0.78), 0.022±0.186 mm (P=0.26), 0.022±0.190 mm (P=0.45), 0.045±0.248 mm (P=0.043), and 0.051±0.313 mm (P=0.40)

  PMID:29191850 · one of two readings recorded this

• annual change in maximum IMT

  no effect, p = 0.26

  0.017±0.190, 0.016±0.225, 0.017±0.263, 0.002±0.251, and 0.017±0.246 mm in the pravastatin group and 0.008±0.148 mm (P=0.78), 0.022±0.186 mm (P=0.26), 0.022±0.190 mm (P=0.45), 0.045±0.248 mm (P=0.043), and 0.051±0.313 mm (P=0.40)

  PMID:29191850 · one of two readings recorded this

• annual change in maximum IMT

  no effect, p = 0.45

  0.017±0.190, 0.016±0.225, 0.017±0.263, 0.002±0.251, and 0.017±0.246 mm in the pravastatin group and 0.008±0.148 mm (P=0.78), 0.022±0.186 mm (P=0.26), 0.022±0.190 mm (P=0.45), 0.045±0.248 mm (P=0.043), and 0.051±0.313 mm (P=0.40)

  PMID:29191850 · one of two readings recorded this

• annual change in maximum IMT

  decreases, p = 0.043

  0.017±0.190, 0.016±0.225, 0.017±0.263, 0.002±0.251, and 0.017±0.246 mm in the pravastatin group and 0.008±0.148 mm (P=0.78), 0.022±0.186 mm (P=0.26), 0.022±0.190 mm (P=0.45), 0.045±0.248 mm (P=0.043), and 0.051±0.313 mm (P=0.40)

  PMID:29191850 · one of two readings recorded this

• annual change in maximum IMT

  no effect, p = 0.4

  0.017±0.190, 0.016±0.225, 0.017±0.263, 0.002±0.251, and 0.017±0.246 mm in the pravastatin group and 0.008±0.148 mm (P=0.78), 0.022±0.186 mm (P=0.26), 0.022±0.190 mm (P=0.45), 0.045±0.248 mm (P=0.043), and 0.051±0.313 mm (P=0.40)

  PMID:29191850 · one of two readings recorded this

• annual change in mean IMT

  no effect, p = 0.74

  0.011±0.085, 0.023±0.114, 0.017±0.114, 0.018±0.118, and 0.021±0.116 mm in the pravastatin group and 0.008±0.074 mm (P=0.74), 0.020±0.087 mm (P=0.99), 0.017±0.097 mm (P=0.44), 0.030±0.113 mm (P=0.18), and 0.040±0.118 mm (P=0.010)

  PMID:29191850 · one of two readings recorded this

• annual change in mean IMT

  no effect, p = 0.99

  0.011±0.085, 0.023±0.114, 0.017±0.114, 0.018±0.118, and 0.021±0.116 mm in the pravastatin group and 0.008±0.074 mm (P=0.74), 0.020±0.087 mm (P=0.99), 0.017±0.097 mm (P=0.44), 0.030±0.113 mm (P=0.18), and 0.040±0.118 mm (P=0.010)

  PMID:29191850 · one of two readings recorded this

• annual change in mean IMT

  no effect, p = 0.44

  0.011±0.085, 0.023±0.114, 0.017±0.114, 0.018±0.118, and 0.021±0.116 mm in the pravastatin group and 0.008±0.074 mm (P=0.74), 0.020±0.087 mm (P=0.99), 0.017±0.097 mm (P=0.44), 0.030±0.113 mm (P=0.18), and 0.040±0.118 mm (P=0.010)

  PMID:29191850 · one of two readings recorded this

• annual change in mean IMT

  no effect, p = 0.18

  0.011±0.085, 0.023±0.114, 0.017±0.114, 0.018±0.118, and 0.021±0.116 mm in the pravastatin group and 0.008±0.074 mm (P=0.74), 0.020±0.087 mm (P=0.99), 0.017±0.097 mm (P=0.44), 0.030±0.113 mm (P=0.18), and 0.040±0.118 mm (P=0.010)

  PMID:29191850 · one of two readings recorded this

• annual change in mean IMT

  decreases, p = 0.01

  0.011±0.085, 0.023±0.114, 0.017±0.114, 0.018±0.118, and 0.021±0.116 mm in the pravastatin group and 0.008±0.074 mm (P=0.74), 0.020±0.087 mm (P=0.99), 0.017±0.097 mm (P=0.44), 0.030±0.113 mm (P=0.18), and 0.040±0.118 mm (P=0.010)

  PMID:29191850 · one of two readings recorded this

• annual change in mean IMT

  no effect, p = 0.69

  0.012±0.084, 0.024±0.101, 0.018±0.108, 0.019±0.115, and 0.022±0.108 mm in the pravastatin group and 0.010±0.075 mm (P=0.69), 0.021±0.088 mm (P=0.89), 0.020±0.097 mm (P=0.49), 0.035±0.1138 mm (P=0.15), and 0.044±0.123 mm (P=0.016)

  PMID:29191850 · one of two readings recorded this

• annual change in mean IMT

  no effect, p = 0.89

  0.012±0.084, 0.024±0.101, 0.018±0.108, 0.019±0.115, and 0.022±0.108 mm in the pravastatin group and 0.010±0.075 mm (P=0.69), 0.021±0.088 mm (P=0.89), 0.020±0.097 mm (P=0.49), 0.035±0.1138 mm (P=0.15), and 0.044±0.123 mm (P=0.016)

  PMID:29191850 · one of two readings recorded this

• annual change in mean IMT

  no effect, p = 0.49

  0.012±0.084, 0.024±0.101, 0.018±0.108, 0.019±0.115, and 0.022±0.108 mm in the pravastatin group and 0.010±0.075 mm (P=0.69), 0.021±0.088 mm (P=0.89), 0.020±0.097 mm (P=0.49), 0.035±0.1138 mm (P=0.15), and 0.044±0.123 mm (P=0.016)

  PMID:29191850 · one of two readings recorded this

• annual change in mean IMT

  no effect, p = 0.15

  0.012±0.084, 0.024±0.101, 0.018±0.108, 0.019±0.115, and 0.022±0.108 mm in the pravastatin group and 0.010±0.075 mm (P=0.69), 0.021±0.088 mm (P=0.89), 0.020±0.097 mm (P=0.49), 0.035±0.1138 mm (P=0.15), and 0.044±0.123 mm (P=0.016)

  PMID:29191850 · one of two readings recorded this

• annual change in mean IMT

  decreases, p = 0.016

  0.012±0.084, 0.024±0.101, 0.018±0.108, 0.019±0.115, and 0.022±0.108 mm in the pravastatin group and 0.010±0.075 mm (P=0.69), 0.021±0.088 mm (P=0.89), 0.020±0.097 mm (P=0.49), 0.035±0.1138 mm (P=0.15), and 0.044±0.123 mm (P=0.016)

  PMID:29191850 · one of two readings recorded this

• atherothrombotic infarction recurrence

  unclear

  atherothrombotic infarction tended to occur less frequently in the pravastatin group than in the control group (0.27 versus 0.71%/y; adjusted HR, 0.41; 95% CI, 0.15–1.15

  PMID:29191850 · one of two readings recorded this

• baseline maximum IMT of the common carotid artery

  no effect, p = 0.56

  Baseline maximum IMT (max IMT) was 1.195±0.331 mm in the pravastatin group and 1.182±0.314 mm in the control group (P=0.56)

  PMID:29191850 · one of two readings recorded this

• baseline mean IMT of the common carotid artery

  no effect, p = 0.99

  Baseline mean IMT (mean±SD) was 0.887±0.155 mm in the pravastatin group and 0.887±0.152 mm in the control group (P=0.99)

  PMID:29191850 · one of two readings recorded this

• HDL cholesterol, between-group over 5 years

  no effect

  Not recorded as a finding: Sentence is agentless and never names pravastatin, so it does not support the claim alone

  High-density lipoprotein cholesterol was not significantly different between the 2 groups.

  PMID:29191850 · one of two readings recorded this

• ischemic stroke recurrence

  no effect

  ischemic stroke (2.09 versus 2.33%/y; adjusted HR, 0.92; 95% CI, 0.59–1.42)

  PMID:29191850 · one of two readings recorded this

• lacunar infarction recurrence

  no effect

  lacunar infarction (1.20 versus 1.14%/y; adjusted HR, 1.07; 95% CI, 0.59–1.93)

  PMID:29191850 · one of two readings recorded this

• LDL cholesterol reduction

  decreases

  Total cholesterol and LDLC were significantly reduced with 10 mg daily of pravastatin by 12% and 19%, respectively, at the 1-year follow-up and continuously thereafter

  PMID:29191850 · one of two readings recorded this

• total cholesterol reduction

  decreases

  Total cholesterol and LDLC were significantly reduced with 10 mg daily of pravastatin by 12% and 19%, respectively, at the 1-year follow-up and continuously thereafter

  PMID:29191850 · one of two readings recorded this

• total stroke and transient ischemic attack recurrence

  no effect

  total stroke and transient ischemic attack (2.58 versus 2.89%/y; adjusted HR, 0.91; 95% CI, 0.61–1.35)

  PMID:29191850 · one of two readings recorded this

• total stroke recurrence

  no effect

  total stroke (2.27 versus 2.66%/y; adjusted HR, 0.87; 95% CI, 0.58–1.33)

  PMID:29191850 · one of two readings recorded this

• triglycerides, average of differences

  decreases, p = 0.023

  The average of differences for triglycerides until 5 years was significantly reduced with 10 mg daily of pravastatin(P=0.023)

  PMID:29191850 · one of two readings recorded this

• use of antihyperlipidemic drugs other than statin

  Of these, 28 (7.2%) and 40 (9.9%) patients, respectively, received antihyperlipidemic drugs except statin

  PMID:29191850 · one of two readings recorded this

• 10-year projected CHD-free restricted mean survival time difference

  increases

  the treated individuals gain 77.9 days (95% CI, 3.8 to 159.6) of CHD-free survival

  PMID:30251369 · one of two readings recorded this

• 10-year projected restricted mean survival time difference (all-cause)

  decreases

  The 10-year RMST difference estimated from parametric models showed that pravastatin-treated individuals live 108.1 days shorter (95% CI, −204.5 to −14.1)

  PMID:30251369 · one of two readings recorded this

• 6-year CHD-free restricted mean survival time

  no effect, p = 0.209

  The 6-year CHD-free mean survival time was longer by 18.7 days (95% CI, −10.4 to 47.8) in those assigned to pravastatin than in usual-care patients (2088.1 vs 2069.4 days), but this was not statistically significant (p=0.209)

  PMID:30251369 · one of two readings recorded this

• 6-year restricted mean survival time (all-cause mortality)

  decreases, p = 0.047

  Over 6 years, individuals who were randomized to pravastatin lived, on average, 2008.1 days; this was statistically significantly shorter by 33.7 days (95% CI, −67.0 to −0.5; p=0.047)

  PMID:30251369 · one of two readings recorded this

• 6-year restricted mean survival time (all-cause mortality)

  than usual-care patients who lived, on average, 2041.8 days

  PMID:30251369 · one of two readings recorded this

• 6-year restricted mean survival time (days alive) for all-cause mortality and CHD-free restricted mean survival time, pravastatin 40 mg daily versus usual care, reconstructed from published ALLHAT-LLT survival curves

  decreases, difference -33.7 days (95% CI -67.0 to -0.5) in 6-year restricted mean survival time, p = 0.047

  Not recorded as a finding: a node exists but the paper states a different instrument or population

  Over 6 years, individuals who were randomized to pravastatin lived, on average, 2008.1 days; this was statistically significantly shorter by 33.7 days (95% CI, −67.0 to −0.5; p=0.047) than usual-care patients who lived, on average, 2041.8 days (Table and Figure Panel A).

  PMID:30251369 · one of two readings recorded this

• 6-year restricted mean survival time (days of survival) and CHD-free restricted mean survival time, pravastatin 40 mg/d versus usual care, reconstructed from published ALLHAT-LLT survival curves in adults aged 65 and older

  decreases, difference -33.7 days (95% CI -67.0 to -0.5) in all-cause survival time over 6 years, p = 0.047

  Not recorded as a finding: a node exists but the paper states a different instrument or population

  Over 6 years, individuals who were randomized to pravastatin lived, on average, 2008.1 days; this was statistically significantly shorter by 33.7 days (95% CI, −67.0 to −0.5; p=0.047) than usual-care patients who lived, on average, 2041.8 days (Table and Figure Panel A).

  PMID:30251369 · one of two readings recorded this

• adiponectin effect by proportion of male participants (meta-regression)

  increases, p = 0.03

  coefficient: 0.015, P=0.03

  PMID:31190742 · one of two readings recorded this

• circulating adiponectin by disease status (MetS/IGT/DM vs hyperlipidemic/hypercholesterolemic)

  no effect, p = 0.49

  P for subgroup difference =0.49

  PMID:31190742 · one of two readings recorded this

• circulating adiponectin, double-blind placebo-controlled RCTs only (sensitivity subset)

  increases, WMD 0.82 µg/mL; 95% CI 0.17-1.47, p = 0.01

  Not recorded as a finding: Subset analysis of the same endpoint; whole-population estimate recorded instead

  Subsequent analyses by including four comparisons from RCTs of DB and PC design further confirmed the results, which showed an even larger increment of circulating adiponectin after pravastatin treatment (WMD =0.82 µg/mL; 95% CI, 0.17–1.47 µg/mL; P=0.01; Figure 2B) with considerable heterogeneity (I =62%).

  PMID:31190742 · one of two readings recorded this

• circulating adiponectin

  increases, p = 0.007, n = 595

  WMD =0.63 µg/mL; 95% CI, 0.17–1.09 µg/mL; P=0.007

  PMID:31190742 · one of two readings recorded this

• circulating adiponectin

  increases, p = 0.01

  WMD =0.82 µg/mL; 95% CI, 0.17–1.47 µg/mL; P=0.01

  PMID:31190742 · one of two readings recorded this

• circulating adiponectin

  no effect, p = 0.31

  WMD =0.27 µg/mL; 95% CI, −0.26–0.80 µg/mL; I =0%; P=0.31

  PMID:31190742 · one of two readings recorded this

• circulating adiponectin

  no effect, p = 0.94

  WMD =−0.04 µg/mL; 95% CI, −1.01 to 0.93 µg/mL; P=0.94

  PMID:31190742 · one of two readings recorded this

• circulating adiponectin

  increases, p = 0.008

  WMD =1.41 µg/mL; 95% CI, 0.58–2.23 µg/mL; P=0.008

  PMID:31190742 · one of two readings recorded this

• circulating adiponectin

  increases, p = 0.001

  WMD =1.01 µg/mL; 95% CI, 0.43–1.59 µg/mL; P<0.001

  PMID:31190742 · one of two readings recorded this

• publication bias (Egger test) for adiponectin effect

  no effect, p = 0.47

  No significant publication biases were indicated by the funnel plot or the results of Egger’s significance test for the effect of pravastatin on circulating adiponectin (P=0.47)

  PMID:31190742 · one of two readings recorded this

• benefit of pravastatin on cardiovascular events by quartile of change in PI(36:2)/PC(38:4)

  no effect

  Stratification of patients into quartiles of change in PI(36:2)/PC(38:4) indicated no benefit of pravastatin in the fourth quartile

  PMID:31292301 · one of two readings recorded this

• change in 342 plasma lipid species between baseline and 1 year in a LIPID trial subcohort, linear regression on pravastatin treatment, and mediation of cardiovascular event risk reduction by the PI(36:2)/PC(38:4) ratio

  Not recorded as a finding: this platform holds no node for the endpoint

  Pravastatin treatment was associated with changes in 206 lipids.

  PMID:31292301 · one of two readings recorded this

• number of plasma lipids associated with pravastatin treatment

  modulates, n = 342

  Pravastatin treatment was associated with changes in 206 lipids

  PMID:31292301 · one of two readings recorded this

• proportion of treatment effect mediated by change in PI(36:2)/PC(38:4)

  unclear

  Change in PI(36:2)/PC(38:4) mediated 58% of the treatment effect

  PMID:31292301 · one of two readings recorded this

• relative risk reduction (RRR) for cardiovascular events

  decreases

  The RRR from pravastatin treatment for cardiovascular events decreased from 23.5% to 16.6% after adjustment for clinical risk factors and change in LDL-cholesterol (LDL-C)

  PMID:31292301 · one of two readings recorded this

• relative risk reduction (RRR) for cardiovascular events

  decreases

  and to 3.0% after further adjustment for the change in the lipid ratio PI(36:2)/PC(38:4)

  PMID:31292301 · one of two readings recorded this

• relative risk reduction (RRR) for cardiovascular events

  decreases

  The RRR from pravastatin treatment for cardiovascular events decreased from 23.5% to 16.6%

  PMID:31292301 · one of two readings recorded this

• serum HDL cholesterol (median)

  Baseline | 8 | 54 (30, 83) | 6 | 61 (46, 87) | 7 | 61 (33, 82)

  PMID:31477152 · one of two readings recorded this

• serum HDL cholesterol (median)

  Week 2 | 6 | 64 (34, 79) | 5 | 64 (51, 82) | 5 | 60 (36, 75)

  PMID:31477152 · one of two readings recorded this

• serum HDL cholesterol (median)

  Week 4 | 3 | 40 (38, 62) | 4 | 60 (47, 72) | 3 | 59 (32, 60)

  PMID:31477152 · one of two readings recorded this

• serum hsCRP by immunoturbidimetric assay and LDL cholesterol by homogeneous enzymatic colorimetric assay, medians at baseline, week 2 and week 4 in an open-label three-arm pilot (aspirin 162 mg, pravastatin 40 mg, or both); no untreated or placebo arm

  decreases

  Not recorded as a finding: the comparison was against another active treatment

  In the pravastatin and combined groups, median LDL cholesterol decreased between baseline and week 2, then rose slightly between weeks 2 and 4.

  PMID:31477152 · one of two readings recorded this

• serum hsCRP decrease from baseline to week 2

  decreases

  hsCRP levels decreased from baseline to week 2 in 2 of 3 women in the aspirin group, 4 of 4 women in the pravastatin group, and 2 of 2 women in the combined group

  PMID:31477152 · one of two readings recorded this

• serum hsCRP (median)

  Baseline | 8 | 2.1 (0.2, 4.9) | 7 | 3.3 (0.4, 8.8) | 6 | 3.6 (0.3, 12.0)

  PMID:31477152 · one of two readings recorded this

• serum hsCRP (median)

  decreases

  Week 2 | 7 | 1.0 (0.2, 4.2) | 7 | 2.9 (0.3, 5.1) | 5 | 1.4 (0.3, 16.2)

  PMID:31477152 · one of two readings recorded this

• serum hsCRP (median)

  decreases

  Week 4 | 3 | 2.3 (0.8, 4.0) | 4 | 1.1 (0.6, 4.5) | 4 | 0.9 (0.3, 11.1)

  PMID:31477152 · one of two readings recorded this

• serum IL-1 (median)

  Baseline | 8 | 3.9 (3.9, 3.9) | 7 | 3.9 (3.9, 4.0) | 7 | 3.9 (3.9, 4.0)

  PMID:31477152 · one of two readings recorded this

• serum IL-1 (median)

  no effect

  Week 2 | 7 | 3.9 (3.9, 3.9) | 7 | 3.9 (3.9, 4.0) | 5 | 3.9 (3.9, 4.0)

  PMID:31477152 · one of two readings recorded this

• serum IL-1 (median)

  no effect

  Week 4 | 3 | 3.9 (3.9, 4.0) | 4 | 4.0 (3.9, 4.0) | 4 | 3.9 (3.9, 4.0)

  PMID:31477152 · one of two readings recorded this

• serum IL-6 (median)

  Baseline | 8 | 1.9 (0.7, 3.0) | 7 | 3.4 (0.7, 41.1) | 6 | 3.2 (0.7, 15.4)

  PMID:31477152 · one of two readings recorded this

• serum IL-6 (median)

  Week 2 | 7 | 2.0 (0.7, 3.1) | 7 | 3.4 (0.7, 8.7) | 5 | 2.4 (0.7, 7.6)

  PMID:31477152 · one of two readings recorded this

• serum IL-6 (median)

  Week 4 | 3 | 2.8 (0.7, 3.1) | 4 | 2.1 (0.7, 5.5) | 4 | 2.4 (0.7, 10.2)

  PMID:31477152 · one of two readings recorded this

• serum LDL cholesterol (median)

  Baseline | 8 | 125 (79, 189) | 6 | 115 (92, 145) | 7 | 102 (7, 122)

  PMID:31477152 · one of two readings recorded this

• serum LDL cholesterol (median)

  decreases

  Week 2 | 6 | 114 (83, 143) | 5 | 87 (58, 130) | 5 | 78 (60, 101)

  PMID:31477152 · one of two readings recorded this

• serum LDL cholesterol (median)

  Week 4 | 3 | 113 (104, 189) | 4 | 104 (73, 130) | 3 | 90 (52, 101)

  PMID:31477152 · one of two readings recorded this

• serum total cholesterol (median)

  Baseline | 8 | 192 (120, 238) | 6 | 180 (159, 256) | 7 | 166 (145, 188)

  PMID:31477152 · one of two readings recorded this

• serum total cholesterol (median)

  Week 2 | 6 | 183 (153, 209) | 5 | 173 (124, 224) | 5 | 148 (137, 191)

  PMID:31477152 · one of two readings recorded this

• serum total cholesterol (median)

  Week 4 | 3 | 186 (157, 232) | 4 | 179 (140, 190) | 3 | 147 (116, 154)

  PMID:31477152 · one of two readings recorded this

• serum triglycerides (median)

  Baseline | 8 | 111 (33, 311) | 6 | 87 (31, 146) | 7 | 75 (73, 121)

  PMID:31477152 · one of two readings recorded this

• serum triglycerides (median)

  Week 2 | 6 | 71 (37, 229) | 5 | 105 (48, 138) | 5 | 98 (54, 166)

  PMID:31477152 · one of two readings recorded this

• serum triglycerides (median)

  Week 4 | 3 | 92 (31, 97) | 4 | 73 (35, 142) | 3 | 113 (73, 206)

  PMID:31477152 · one of two readings recorded this

• 24 hour urinary protein

  no effect

  24 hour urinary protein (g/24 hour) | N = 14 1.81 (4.24) | N = 10 2.97 (3.18) | N = 10 1.23 (1.09) | N = 5 3.78 (3.89) | N = 3 1.11 (0.84) | N = 2 6.66 (0.29) | N = 4 3.37 (3.64) | N = 2 12.42 (7.86) | N = 2 4.34 (3.30) | N = 1 9.90 (–) | N = 1 0.37 (–) | N = 2 0.58 (0.56) | 0.58 (0.18, 0.99) | −1.17 (−3.65, 1.01)

  PMID:31715077 · one of two readings recorded this

• 24 hour urinary protein

  unclear

  24 hour urinary protein (g/24 hour) | N = 14 1.81 (4.24) | N = 10 2.97 (3.18) | N = 10 1.23 (1.09) | N = 5 3.78 (3.89) | N = 3 1.11 (0.84) | N = 2 6.66 (0.29) | N = 4 3.37 (3.64) | N = 2 12.42 (7.86) | N = 2 4.34 (3.30) | N = 1 9.90 (–) | N = 1 0.37 (–) | N = 2 0.58 (0.56) | 0.58 (0.18, 0.99) | −1.17 (−3.65, 1.01)

  PMID:31715077 · one of two readings recorded this

• birthweight of surviving infants

  no effect

  mean birthweights were 1.1 kg (SD 0.6) and 1.1 kg (SD 0.5) for babies born to mothers in the pravastatin and placebo groups, respectively

  PMID:31715077 · one of two readings recorded this

• diastolic blood pressure

  no effect

  Blood pressure (systolic/ diastolic mmHg) | N = 30 159.9 (15.6)/ 97.9 (5.4) | N = 32 167.1 (18.3)/99.6 (6.9) | N = 29 146.6 (16.3)/ 88.4 (9.9) | N = 31 145.4(11.8)/ 89.4 (5.9) | N = 24 140.8 (8.9)/ 85.7 (8.8) | N = 24 146.9 (11.8)/ 91.2 (9.8) | N = 16 145.3 (11.8)/ 88.1 (9.4) | N = 13 147.0 (15.3)/ 88.2 (11.3) | N = 5 137.1 (17.8)/ 85.6 (12.7) | N = 5 138.6 (8.2)/ 84.7 (9.4) | N = 1 135.5 (–)/ 75.8 (–) | N = 4 151.2 (22.6)/ 91.2 (13.2) | Systolic − 1.4 (−8.6, 5.7) Diastolic − 1.0 (−5.0, 3.1) | Systolic − 0.5 (−6.0, 5.0) Diastolic − 2.0 (−5.9, 1.9)

  PMID:31715077 · one of two readings recorded this

• diastolic blood pressure

  no effect

  Blood pressure (systolic/ diastolic mmHg) | N = 30 159.9 (15.6)/ 97.9 (5.4) | N = 32 167.1 (18.3)/99.6 (6.9) | N = 29 146.6 (16.3)/ 88.4 (9.9) | N = 31 145.4(11.8)/ 89.4 (5.9) | N = 24 140.8 (8.9)/ 85.7 (8.8) | N = 24 146.9 (11.8)/ 91.2 (9.8) | N = 16 145.3 (11.8)/ 88.1 (9.4) | N = 13 147.0 (15.3)/ 88.2 (11.3) | N = 5 137.1 (17.8)/ 85.6 (12.7) | N = 5 138.6 (8.2)/ 84.7 (9.4) | N = 1 135.5 (–)/ 75.8 (–) | N = 4 151.2 (22.6)/ 91.2 (13.2) | Systolic − 1.4 (−8.6, 5.7) Diastolic − 1.0 (−5.0, 3.1) | Systolic − 0.5 (−6.0, 5.0) Diastolic − 2.0 (−5.9, 1.9)

  PMID:31715077 · one of two readings recorded this

• infant survival

  unclear

  All 30 infants born to mothers who received pravastatin survived, whereas 29 of 32 infants from women who received placebo survived

  PMID:31715077 · one of two readings recorded this

• maternal diastolic blood pressure at 6 weeks postpartum

  no effect

  By 6 weeks postpartum, maternal blood pressure had returned to normal in both groups (pravastatin group mean blood pressure 128.1 mmHg [SD 18.2]/80.4 mmHg [SD 13.0]; placebo group mean blood pressure 128.0 mmHg [SD 13.0]/79.4 mmHg [SD 11.4])

  PMID:31715077 · one of two readings recorded this

• maternal plasma PlGF

  no effect, p = 0.4

  PlGF (pg/ml) | N = 29 23.53 (46.60) | N = 31 20.37 (40.33) | N = 27 37.17 (121.40) | N = 29 18.67 (35.27) | N = 20 15.98 (13.04) | N = 19 25.39 (59.77) | N = 15 57.56 (177.53) | N = 10 36.13 (89.51) | N = 5 82.13 (150.63) | N = 4 40.15 (39.81) | N = 1 528.60 (–) | N = 3 43.84 (58.80) | 8.94 (−13.33, 31.20) P = 0.4 | 8.77 (−11.61, 29.15) P = 0.4

  PMID:31715077 · one of two readings recorded this

• maternal plasma PlGF

  no effect, p = 0.4

  PlGF (pg/ml) | N = 29 23.53 (46.60) | N = 31 20.37 (40.33) | N = 27 37.17 (121.40) | N = 29 18.67 (35.27) | N = 20 15.98 (13.04) | N = 19 25.39 (59.77) | N = 15 57.56 (177.53) | N = 10 36.13 (89.51) | N = 5 82.13 (150.63) | N = 4 40.15 (39.81) | N = 1 528.60 (–) | N = 3 43.84 (58.80) | 8.94 (−13.33, 31.20) P = 0.4 | 8.77 (−11.61, 29.15) P = 0.4

  PMID:31715077 · one of two readings recorded this

• maternal plasma sFlt-1 (primary outcome)

  no effect, p = 0.5

  differences were small and not statistically different over days 1–3 (292 pg/ml, 95% CI −1175 to 592; P = 0.5)

  PMID:31715077 · one of two readings recorded this

• maternal plasma sFlt-1

  no effect, p = 0.9

  days 1–14 (48 pg/ml, 95% CI −1009 to 913; P = 0.9)

  PMID:31715077 · one of two readings recorded this

• maternal plasma sFlt-1

  sFLT‐1 (pg/ml) | N = 29 8296 (5046) | N = 31 11 065 (6665) | N = 27 8516 (4795) | N = 29 12 241 (6390) | N = 19 9210 (5037) | N = 19 106 09 (5367) | N = 15 7518 (5837) | N = 10 8132 (4050) | N = 5 12 811 (8937) | N = 4 8458 (4109) | N = 1 1293 (–) | N = 3 12 205 (10341) | −292 (−1175, 592) P = 0.5 | −49 (−1010, 913) P = 0.9

  PMID:31715077 · one of two readings recorded this

• maternal sFlt-1:PlGF ratio

  no effect, p = 0.7

  sFLT‐1/PlGF | N = 29 979 (1076) | N = 31 1782 (1697) | N = 27 947 (884)e | N = 29 2012 (1779)e | N = 19 1078 (940) | N = 19 1747 (1388) | N = 15 958 (793) | N = 10 1479 (1228) | N = 5 1557 (2118) | N = 4 653 (756) | N = 1 2 (–) | N = 3 2361 (3696) | −37 (−364, 291) P = 0.8 | −54 (−364, 255) P = 0.7

  PMID:31715077 · one of two readings recorded this

• maternal sFlt-1:PlGF ratio

  no effect, p = 0.8

  sFLT‐1/PlGF | N = 29 979 (1076) | N = 31 1782 (1697) | N = 27 947 (884)e | N = 29 2012 (1779)e | N = 19 1078 (940) | N = 19 1747 (1388) | N = 15 958 (793) | N = 10 1479 (1228) | N = 5 1557 (2118) | N = 4 653 (756) | N = 1 2 (–) | N = 3 2361 (3696) | −37 (−364, 291) P = 0.8 | −54 (−364, 255) P = 0.7

  PMID:31715077 · one of two readings recorded this

• maternal systolic blood pressure at 6 weeks postpartum

  no effect

  By 6 weeks postpartum, maternal blood pressure had returned to normal in both groups (pravastatin group mean blood pressure 128.1 mmHg [SD 18.2]/80.4 mmHg [SD 13.0]; placebo group mean blood pressure 128.0 mmHg [SD 13.0]/79.4 mmHg [SD 11.4])

  PMID:31715077 · one of two readings recorded this

• mean maternal plasma sFlt-1 over the first 3 days after randomisation (primary), measured by BRAHMS Kryptor; also PlGF, sFlt-1:PlGF ratio, time from randomisation to childbirth, necrotising enterocolitis and retinopathy of prematurity counts, in early-onset pre-eclampsia, pravastatin 40 mg daily versus placebo

  no effect, difference 292 pg/ml (95% CI -1175 to 592) over days 1-3, p = 0.5

  Not recorded as a finding: this platform holds no node for the endpoint

  Maternal plasma levels of sFlt‐1 were lower in the pravastatin group compared with placebo, although differences were small and not statistically different over days 1–3 (292 pg/ml, 95% CI −1175 to 592; P = 0.5) and days 1–14 (48 pg/ml, 95% CI −1009 to 913; P = 0.9).

  PMID:31715077 · one of two readings recorded this

• median time from randomisation to childbirth

  no effect

  The median time from randomisation to childbirth was 9 days (interquartile range [IQR] 5–14 days) for women in the pravastatin group and 7 days (IQR 4–11 days) for the placebo group

  PMID:31715077 · one of two readings recorded this

• necrotising enterocolitis in babies

  decreases

  a higher proportion of babies developed necrotising enterocolitis in the placebo group (n = 6; 20%) compared with the pravastatin group (n = 3; 10%)

  PMID:31715077 · one of two readings recorded this

• necrotising enterocolitis in infants of women with early-onset pre-eclampsia, pravastatin 40 mg daily versus placebo (descriptive, untested; Bell stage not stated). The primary endpoint, maternal plasma sFlt-1 over days 1-3, has no outcome node and was null (difference -292 pg/ml, 95% CI -1175 to 592, P = 0.5). Retinopathy of prematurity was reported the same way (8 of 29, 28% placebo versus 4 of 30, 13% pravastatin).

  Not recorded as a finding: the direction is carried only as a signed number

  However, a higher proportion of babies developed necrotising enterocolitis in the placebo group (n = 6; 20%) compared with the pravastatin group (n = 3; 10%).

  PMID:31715077 · one of two readings recorded this

• retinopathy of prematurity in babies

  decreases

  retinopathy of prematurity was more common in the placebo group (n = 8; 28%) compared with the pravastatin group (n = 4; 13%

  PMID:31715077 · one of two readings recorded this

• systolic blood pressure

  no effect

  Blood pressure (systolic/ diastolic mmHg) | N = 30 159.9 (15.6)/ 97.9 (5.4) | N = 32 167.1 (18.3)/99.6 (6.9) | N = 29 146.6 (16.3)/ 88.4 (9.9) | N = 31 145.4(11.8)/ 89.4 (5.9) | N = 24 140.8 (8.9)/ 85.7 (8.8) | N = 24 146.9 (11.8)/ 91.2 (9.8) | N = 16 145.3 (11.8)/ 88.1 (9.4) | N = 13 147.0 (15.3)/ 88.2 (11.3) | N = 5 137.1 (17.8)/ 85.6 (12.7) | N = 5 138.6 (8.2)/ 84.7 (9.4) | N = 1 135.5 (–)/ 75.8 (–) | N = 4 151.2 (22.6)/ 91.2 (13.2) | Systolic − 1.4 (−8.6, 5.7) Diastolic − 1.0 (−5.0, 3.1) | Systolic − 0.5 (−6.0, 5.0) Diastolic − 2.0 (−5.9, 1.9)

  PMID:31715077 · one of two readings recorded this

• systolic blood pressure

  no effect

  Blood pressure (systolic/ diastolic mmHg) | N = 30 159.9 (15.6)/ 97.9 (5.4) | N = 32 167.1 (18.3)/99.6 (6.9) | N = 29 146.6 (16.3)/ 88.4 (9.9) | N = 31 145.4(11.8)/ 89.4 (5.9) | N = 24 140.8 (8.9)/ 85.7 (8.8) | N = 24 146.9 (11.8)/ 91.2 (9.8) | N = 16 145.3 (11.8)/ 88.1 (9.4) | N = 13 147.0 (15.3)/ 88.2 (11.3) | N = 5 137.1 (17.8)/ 85.6 (12.7) | N = 5 138.6 (8.2)/ 84.7 (9.4) | N = 1 135.5 (–)/ 75.8 (–) | N = 4 151.2 (22.6)/ 91.2 (13.2) | Systolic − 1.4 (−8.6, 5.7) Diastolic − 1.0 (−5.0, 3.1) | Systolic − 0.5 (−6.0, 5.0) Diastolic − 2.0 (−5.9, 1.9)

  PMID:31715077 · one of two readings recorded this

• time from randomisation to childbirth

  no effect, p = 0.6

  hazard ratio [HR] 0.84; 95% CI 0.50–1.40) but this difference was not significant (P = 0.6)

  PMID:31715077 · one of two readings recorded this

• time from randomisation to childbirth

  no effect, p = 0.4

  continued their pregnancy for 11 days (IQR 6–14 days) compared with 7 days (IQR 6–11 days) for those who received placebo (HR 0.76; 95% CI 0.41–1.42; P = 0.4)

  PMID:31715077 · one of two readings recorded this

• time to delivery by baseline PlGF (post-hoc predictor)

  decreases, p = 0.03

  only PlGF (HR 0.97; 95% CI 0.94–1.00, P = 0.03) and the sFlt‐1/PlGF ratio (HR 1.33; 95% CI 1.12–1.57, P = 0.0009)

  PMID:31715077 · one of two readings recorded this

• time to delivery by baseline sFlt-1/PlGF ratio (post-hoc predictor)

  increases, p = 0.0009

  only PlGF (HR 0.97; 95% CI 0.94–1.00, P = 0.03) and the sFlt‐1/PlGF ratio (HR 1.33; 95% CI 1.12–1.57, P = 0.0009)

  PMID:31715077 · one of two readings recorded this

• urinary protein:creatinine ratio

  no effect

  Urinary protein: creatine ratio (mg/mmol) | N = 28 3.34 (3.92) | N = 32 4.06 (4.69) | N = 22 3.87 (5.10) | N = 27 5.56 (5.82) | N = 16 6.86 (8.85) | N = 17 7.82 (7.48) | N = 9 7.73 (5.28) | N = 10 8.54 (7.91) | N = 4 8.04 (2.25) | N = 3 1.89 (2.88) | N = 0 (–) | N = 3 3.63 (4.56) | −0.82 (−2.90. 1.26) | −0.87 (−3.30, 1.55)

  PMID:31715077 · one of two readings recorded this

• urinary protein:creatinine ratio

  no effect

  Urinary protein: creatine ratio (mg/mmol) | N = 28 3.34 (3.92) | N = 32 4.06 (4.69) | N = 22 3.87 (5.10) | N = 27 5.56 (5.82) | N = 16 6.86 (8.85) | N = 17 7.82 (7.48) | N = 9 7.73 (5.28) | N = 10 8.54 (7.91) | N = 4 8.04 (2.25) | N = 3 1.89 (2.88) | N = 0 (–) | N = 3 3.63 (4.56) | −0.82 (−2.90. 1.26) | −0.87 (−3.30, 1.55)

  PMID:31715077 · one of two readings recorded this

• birth weight

  no effect

  Birth weight was higher (mean difference 299 grams, 95% CI: −215 – 812)

  PMID:34033812 · one of two readings recorded this

• apparent oral clearance at 20 mg versus 10 mg dose

  no effect

  Nevertheless, the apparent oral clearance values were similar

  PMID:34033812 · one of two readings recorded this

• gestational age at delivery

  no effect

  gestational age at delivery longer (mean difference 1.5 weeks, 95% CI −0.4 – 3.3)

  PMID:34033812 · one of two readings recorded this

• incidence of preeclampsia (with and without severe features, adjudicated by a blinded panel) in pregnant women at high risk, pravastatin 20 mg daily versus placebo; also indicated preterm delivery before 37 weeks and steady-state pravastatin pharmacokinetics in pregnancy

  n = 20

  Not recorded as a finding: this platform holds no node for the endpoint

  In the pravastatin group, two (20%) patients developed preeclampsia without severe features compared with 5 (50%) in the placebo group (all with severe features).

  PMID:34033812 · one of two readings recorded this

• indicated preterm delivery before 37 weeks, pravastatin 20 mg daily versus placebo in 20 pregnant women (pilot trial, safety and pharmacokinetics primary); preeclampsia rate (no node) was reported alongside

  Not recorded as a finding: the direction is carried only as a signed number

  Similarly, three (30%) patients had indicated preterm deliveries before 37 weeks in the pravastatin group compared with six (60%) in the placebo group (Table 4).

  PMID:34033812 · one of two readings recorded this

• indicated preterm delivery before 37 weeks

  decreases

  three (30%) patients had indicated preterm deliveries before 37 weeks in the pravastatin group compared with six (60%) in the placebo group

  PMID:34033812 · one of two readings recorded this

• low-dose aspirin use

  no effect

  overall 70% and not significantly different between the two groups

  PMID:34033812 · one of two readings recorded this

• preeclampsia with severe features

  decreases, p = 0.003

  preeclampsia with severe features was 0% vs. 40% (P=0.003)

  PMID:34033812 · one of two readings recorded this

• preeclampsia without severe features

  decreases

  In the pravastatin group, two (20%) patients developed preeclampsia without severe features compared with 5 (50%) in the placebo group

  PMID:34033812 · one of two readings recorded this

• preeclampsia

  decreases, p = 0.03

  The combined rate of preeclampsia was 10% in the pravastatin group compared with 45% in the placebo group (RR 0.22, 95% CI: 0.05–0.90, P=0.03)

  PMID:34033812 · one of two readings recorded this

• preterm delivery before 37 weeks

  decreases, p = 0.048

  preterm delivery < 37 weeks was 20% compared with 55% (RR0.36, 95% CI: 0.14–0.95, P=0.048)

  PMID:34033812 · one of two readings recorded this

• steady-state Cmax at 20 mg versus 10 mg dose

  increases

  the average maximum concentration and area under the concentration time curve values were more than two-fold higher following 20-mg dosing compared with the 10-mg pravastatin dose

  PMID:34033812 · one of two readings recorded this

• LDL cholesterol

  decreases

  Pravastatin 10 mg/day to 80 mg/day reduced LDL cholesterol by 21.7% to 31.9%, total cholesterol by 16.1% to 23.3%,and triglycerides by 5.8% to 20.0%

  PMID:37721222 · one of two readings recorded this

• triglycerides

  decreases

  Pravastatin 10 mg/day to 80 mg/day reduced LDL cholesterol by 21.7% to 31.9%, total cholesterol by 16.1% to 23.3%,and triglycerides by 5.8% to 20.0%

  PMID:37721222 · one of two readings recorded this

• HDL cholesterol, dose-response across doses

  no effect

  Not recorded as a finding: Sentence reports absence of a DOSE-related effect, not a pravastatin-versus-placebo contrast on HDL-C; not recorded as no_effect

  There was no dose-related effect of pravastatin on blood HDL cholesterol.

  PMID:37721222 · one of two readings recorded this

• HDL cholesterol dose-response

  no effect

  There was no dose-related effect of pravastatin on blood HDL cholesterol

  PMID:37721222 · one of two readings recorded this

• LDL cholesterol dose-response slope per two-fold dose increase

  decreases

  For every two-fold dose increase there was a 3.4% (95% confidence interval (CI) 2.2 to 4.6) decrease in blood LDL cholesterol

  PMID:37721222 · one of two readings recorded this

• total cholesterol dose-response (log dose)

  decreases

  Log dose-response data over the doses of 5 mg to 160 mg revealed strong linear dose-related effects on blood total cholesterol and LDL cholesterol, and a weak linear dose-related effect on blood triglycerides

  PMID:37721222 · one of two readings recorded this

• total cholesterol

  decreases

  Pravastatin 10 mg/day to 80 mg/day reduced LDL cholesterol by 21.7% to 31.9%, total cholesterol by 16.1% to 23.3%,and triglycerides by 5.8% to 20.0%

  PMID:37721222 · one of two readings recorded this

• triglycerides dose-response (log dose)

  decreases

  Log dose-response data over the doses of 5 mg to 160 mg revealed strong linear dose-related effects on blood total cholesterol and LDL cholesterol, and a weak linear dose-related effect on blood triglycerides

  PMID:37721222 · one of two readings recorded this

• withdrawals due to adverse effects, pooled risk ratio versus placebo

  RR 0.81 (95% CI 0.63 to 1.03)

  Not recorded as a finding: Interval spans 1 and no direction word in the sentence; direction_stated_but_not_significant shape.

  The effect of pravastatin compared to placebo on WADES has a risk ratio (RR) of 0.81 (95% CI 0.63 to 1.03).

  PMID:37721222 · one of two readings recorded this

• withdrawals due to adverse effects, pravastatin versus placebo

  RR 0.81 (95% CI 0.63 to 1.03)

  Not recorded as a finding: Sentence carries a risk ratio and interval but no direction word; direction not in words

  The effect of pravastatin compared to placebo on WADES has a risk ratio (RR) of 0.81 (95% CI 0.63 to 1.03).

  PMID:37721222 · one of two readings recorded this

• withdrawals due to adverse effects

  no effect

  The effect of pravastatin compared to placebo on WADES has a risk ratio (RR) of 0.81 (95% CI 0.63 to 1.03)

  PMID:37721222 · one of two readings recorded this

• age at baseline (median)

  unclear, p = 0.01

  Age, median (IQR) | 47 (38–68) | 45.5 (38–57) | 55 (42–68) | 0.01

  PMID:40461956 · one of two readings recorded this

• hs-CRP

  increases, p = 0.02

  the control group demonstrated the sharp increase in the hs-CRP level 3 times higher than the baseline during the early period (0.040 to 0.140 mg/dL, Z score: -2.371, P =.02)

  PMID:40461956 · one of two readings recorded this

• hs-CRP

  decreases, p = 0.03

  Control group | 0.040 (0.040-0.110) | 0.140 (0.050-0.250) | 0.040 (0.030-0.10) | -2.371 | 0.02 | -2.207 | 0.03

  PMID:40461956 · one of two readings recorded this

• hs-CRP

  no effect, p = 0.07

  its level decreased during the early period (0.070 to 0.045 mg/dL, Z score: -1.843, P =.07)

  PMID:40461956 · one of two readings recorded this

• hs-CRP

  no effect, p = 0.33

  changed to plateau during the late period (0.045 to 0.050 mg/dL, Z score: − 0.985, P =.33)

  PMID:40461956 · one of two readings recorded this

• improved/resolved intimal flap on VW-MRI

  no effect

  Improved/resolved | 5 (83.3) | 2 (66.7) | 5 (83.3) | 3 (100.0)

  PMID:40461956 · one of two readings recorded this

The whole record — 254 rows